Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-108210
Filing Date
2025-08-13
Accepted
2025-08-13 18:03:44
Documents
1
Period of Report
2025-08-11

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 3917
  Complete submission text file 0000950170-25-108210.txt   5555
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Issuer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address
Machatha Stephen (Reporting) CIK: 0001836354 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36332 | Film No.: 251213334